new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12016012914005/12/16 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
22016013033305/12/16 Chimeric and humanized anti-histone antibodies
32016012097605/05/16 Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
42016009593904/07/16 Neoadjuvant use of antibody-drug conjugates
52016009041303/31/16 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
62016009042303/31/16 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
72016008200303/24/16 Immunoconjugates with an intracellularly-cleavable linkage
82016006988503/10/16 Detection of early-stage pancreatic adenocarcinoma
92016006070703/03/16 Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
102016004562602/18/16 Methods and compositions for improved labeling of targeting peptides
112016003994102/11/16 Immunotherapy of autoimmune disorders using antibodies which target b-cells
122016003200302/04/16 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
132016003200402/04/16 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
142016003200802/04/16 Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
152016002421201/28/16 Humanized anti-hla-dr antibodies
162016000091501/07/16 Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells
172015036698812/24/15 Antibody-drug conjugates and uses thereof
182015036836212/24/15 Anti-histone therapy for vascular necrosis in severe glomerulonephritis
192015034308712/03/15 Class i anti-cea antibodies and uses thereof
202015034457312/03/15 Humanized anti-cd22 antibody
212015032087211/12/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
222015031528911/05/15 Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
232015030624310/29/15 Antibody-sn-38 immunoconjugates with a cl2a linker
242015030624410/29/15 Anthracycline-antibody conjugates for cancer therapy
252015030752410/29/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
262015028326410/08/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
272015025211009/10/15 Anti-cd19 antibodies
282015023997408/27/15 Humanized rfb4 anti-cd22 antibody
292015022419208/13/15 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
302015021699708/06/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
312015021700608/06/15 Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
322015020231907/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
332015020232007/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
342015019665307/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
352015019665407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
362015019666107/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
372015019666207/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
382015019666407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
392015019666507/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
402015019666607/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
412015018263307/02/15 Immunoconjugates with an intracellularly-cleavable linkage
422015018388007/02/15 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
432015017426906/25/15 Immunoconjugates with an intracellularly-cleavable linkage
442015017427006/25/15 Immunoconjugates with an intracellularly-cleavable linkage
452015016507506/18/15 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
462015016507606/18/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
472015016665906/18/15 Humanized l243 antibodies
482015016666906/18/15 Anti-cd74 immunoconjugates and methods of use
492015015096906/04/15 Chimeric and humanized anti-histone antibodies
502015013276805/14/15 Anti-pancreatic cancer antibodies
512015012538605/07/15 Humanized anti-ceacam5 antibody and uses thereof
522015011127904/23/15 Class i anti-cea antibodies and uses thereof
532015009445604/02/15 Anthracycline-antibody conjugates for cancer therapy
542015008648203/26/15 Dye conjugated peptides for fluorescent imaging
552015005743202/26/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
562015003868602/05/15 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
572015001851601/15/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
582014037717312/25/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
592014037717712/25/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
602014037728712/25/14 Anti-trop-2 antibody-drug conjugates and uses thereof
612014036992712/18/14 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
622014028686009/25/14 Immunoconjugates with an intracellularly-cleavable linkage
632014028686109/25/14 Rs7 antibodies
642014023420908/21/14 Chimeric and humanized anti-histone antibodies
652014022717808/14/14 Humanized anti-hla-dr antibodies
662014022717908/14/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
672014022718008/14/14 Antibody-sn-38 immunoconjugates with a cl2a linker
682014022854108/14/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
692014021991408/07/14 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
702014021995608/07/14 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
712014021242507/31/14 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
722014019335907/10/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
732014017829406/26/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
742014017006506/19/14 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
752014015427306/05/14 Anthracycline-antibody conjugates for cancer therapy
762014014738205/29/14 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
772014014092405/22/14 Humanized l243 antibodies
782014012003505/01/14 Rs7 antibodies
792014011286404/24/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
802014011286504/24/14 Anti-cd19 antibodies
812014010581904/17/14 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
822014009925804/10/14 Camptothecin-binding moiety conjugates
832014008683003/27/14 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
842014008683203/27/14 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
852014007962903/20/14 Class i anti-cea antibodies and uses thereof
862014005806702/27/14 Immunoconjugates with an intracellularly-cleavable linkage
872014004463902/13/14 Antibody therapy
882014004464002/13/14 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
892014003754302/06/14 Anti-pancreatic cancer antibodies
902014003826102/06/14 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
912014003828402/06/14 Mammalian cell lines for increasing longevity and protein yield from a cell culture
922014001716801/16/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
932014001719701/16/14 Anti-cd19 antibodies
942014000407801/02/14 Immunoconjugates with an intracellularly-cleavable linkage
952013031582111/28/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
962013030917711/21/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
972013021656108/22/13 Immunoconjugates with an intracellularly-cleavable linkage
982013020935608/15/13 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
992013021104408/15/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1002013017749807/11/13 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1012013017752607/11/13 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1022013017106407/04/13 Anti-cd74 immunoconjugates and methods of use
1032013017106507/04/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1042013017117607/04/13 Anthracycline-antibody conjugates for cancer therapy
1052013016421406/27/13 Antibody-based depletion of antigen-presenting cells and dendritic cells
1062013016478306/27/13 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1072013015669106/20/13 Antibody therapy
1082013014278706/06/13 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
1092013014329606/06/13 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1102013012191305/16/13 Anti-cd19 antibodies
1112013012347305/16/13 Bispecific antibody targeting a complement factor or complement regulatory protein
1122013009503404/18/13 Anti-cd74 immunoconjugates and methods
1132013009045804/11/13 Immunoconjugates with an intracellularly-cleavable linkage
1142013007818203/28/13 Structural variants of antibodies for improved therapeutic characteristics
1152013007826303/28/13 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
1162013007132003/21/13 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1172013007140603/21/13 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
1182013007265903/21/13 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1192013003986102/14/13 Dye conjugated peptides for fluorescent imaging
1202013003449202/07/13 Class i anti-cea antibodies and uses thereof
1212012032856412/27/12 Camptothecin-binding moiety conjugates
1222012032863412/27/12 Immunoconjugates with an intracellularly-cleavable linkage
1232012032155312/20/12 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
1242012028217811/08/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1252012027610011/01/12 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1262012023095309/13/12 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1272012021496908/23/12 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1282012019632608/02/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1292012018954207/26/12 Anti-cd19 antibodies
1302012018347207/19/12 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1312012018355007/19/12 Therapeutic using a bispecific antibody
1322012014908506/14/12 Fusion proteins containing recombinant cytotoxic rnases
1332012014137206/07/12 Rs7 antibodies
1342012014137506/07/12 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
1352012013492005/31/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1362012011455605/10/12 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1372012010723505/03/12 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1382012008829904/12/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1392012008261704/05/12 Immunoconjugates with an intracellularly-cleavable linkage
1402012007672703/29/12 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1412012006399303/15/12 Therapeutic and diagnostic conjugates for use with multispecific antibodies
1422012003979702/16/12 Antibody therapy
1432012004043102/16/12 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1442012003418502/09/12 Anti-cd20 antibodies and fusion proteins therof and methods of use
1452011031153112/22/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1462011030563112/15/11 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1472011030006612/08/11 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1482011029351312/01/11 Immunoconjugates with an intracellularly-cleavable linkage
1492011028691811/24/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1502011028080111/17/11 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1512011027470411/10/11 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1522011025605310/20/11 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1532011024384110/06/11 Antibody-based depletion of antigen-presenting cells and dendritic cells
1542011024454610/06/11 Internalizing anti-cd74 antibodies and methods of use
1552011023630409/29/11 Structural variants of antibodies for improved therapeutic characteristics
1562011023640409/29/11 Methods for protein expression in mammalian cells in serum-free medium
1572011022940709/22/11 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1582011022364509/15/11 Multivalent carriers of bi-specific antibodies
1592011019502308/11/11 Internalizing anti-cd74 antibodies and methods of use
1602011018908508/04/11 Antibody therapy
1612011018926808/04/11 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1622011017112607/14/11 Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1632011016507207/07/11 Detection of early-stage pancreatic adenocarcinoma
1642011016507307/07/11 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1652011011701005/19/11 Methods and compositions for administering therapeutic and diagnostic agents
1662011011710505/19/11 Method of treating immune disease using b-cell antibodies
1672011011085405/12/11 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1682011007623303/31/11 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1692011007015503/24/11 Anti-cd74 immunoconjugates and methods
1702011007015603/24/11 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1712011006465303/17/11 Class i anti-cea antibodies and uses thereof
1722011005248903/03/11 Anti-cd19 antibodies
1732010031116212/09/10 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1742010028490611/11/10 Internalizing anti-cd74 antibodies and methods of use
1752010027263610/28/10 Anti-cd74 immunoconjugates and methods of use
1762010026649610/21/10 Anti-cd74 immunoconjugates and methods of use
1772010026649710/21/10 Internalizing anti-cd74 antibodies and methods of use
1782010023377909/16/10 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1792010022688409/09/10 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1802010022117509/02/10 Antibody therapy
1812010022117709/02/10 Rs7 antibodies
1822010021666208/26/10 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1832010020296108/12/10 D-amino acid peptides
1842010019626608/05/10 Humanized anti-hla-dr antibodies
1852010019626708/05/10 Humanized l243 antibodies
1862010019698908/05/10 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1872010018964107/29/10 Novel strategies for improved cancer vaccines
1882010015880206/24/10 Chimeric, human and humanized anti-csap monoclonal antibodies
1892010015880306/24/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1902010013662606/03/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1912010010458904/29/10 Immunoconjugates with an intracellularly-cleavable linkage
1922010007484003/25/10 Anthracycline-antibody conjugates for cancer therapy
1932010006813603/18/10 Anti-cd19 antibodies
1942010004054102/18/10 Structural variants of antibodies for improved therapeutic characteristics
1952010003473802/11/10 Structural variants of antibodies for improved therapeutic characteristics
1962010001504601/21/10 Camptothecin-binding moiety conjugates
1972010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1982010000885501/14/10 Production and use of novel peptide-based agents with bispecific antibodies
1992010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
2002009030458012/10/09 Anti-pancreatic cancer antibodies
2012009029903312/03/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2022009029109311/26/09 Immunoconjugates with an intracellularly-cleavable linkage
2032009028575211/19/09 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
2042009027464911/05/09 Bispecific antibody point mutations for enhancing rate of clearance
2052009025273110/08/09 Multivalent carriers of bi-specific antibodies
2062009025317910/08/09 Mammalian cell lines for increasing longevity and protein yield from a cell culture
2072009024613010/01/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2082009024613110/01/09 Production and use of novel peptide-based agents for use with bi-specific antibodies
2092009024621410/01/09 Fusion proteins containing recombinant cytotoxic rnases
2102009023875709/24/09 Methods and compositions for administering therapeutic and diagnostic agents
2112009024003709/24/09 Humanized antibodies and methods of humanizing antibodies
2122009018597407/23/09 Chimeric, human and humanized anti-granulocyte antibodies and methods of use
2132009015516606/18/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2142009015525306/18/09 Anti-cd20 antibodies and fusion proteins therof and methods of use
2152009011114304/30/09 Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
2162009009259804/09/09 Antibody therapy
2172010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
2182010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###